There is also other evidence indicating that the majority of CD4+CD25+Foxp3+ Tregs are TNFR2+, and they expressed TNFR2 with the highest intensity in the TDLNs of breast cancer, up to 90.5% ± 11.3%, when compared with other CD4+ T cells, which highlights the importance of TNFR2 in Tregs (53). This evidence concerns the gene CD4 and breast carcinoma.